Gubra A/S (CPH:GUBRA), a provider of pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, announced on Thursday that pharmaceutical company Boehringer Ingelheim has decided to discontinue the development of BI 1820237, a long-acting neuropeptide Y receptor type 2 (NPY2) agonist, for the treatment of obesity.

The decision does not impact the other three ongoing collaborations between Gubra and Boehringer Ingelheim, including the development of a potential first-in-class triple agonist obesity treatment currently in Phase 1 clinical trials.